



Diabetes and Cardiovascular Disease
EASD Study Group

**7th Annual Meeting
Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group
November 6 – 8, 2014
Milan, Italy**

Thursday November 6th

17.00 – 17.15	Welcome A. Ceriello (Spain)
17.15 - 19.15	Diet, new biomarkers and CVD in diabetes Chairmen: E. Standl (Germany) J. Skrha (Cech. Rep)
17.15 – 17.35	The “meaning” of the Mediterranean diet D. Giugliano (Italy)
17.35 – 17.55	Are there any reliable biochemical markers of vascular disease in diabetes? J. Skrha (Cech. Rep)
17.55 – 18.15	Clinical implications of oxidative stress in diabetes A. Ceriello (Spain)
18.15 – 18.35	Identification of relevant biomarkers for type 2 diabetes S. J. Bakker (Netherlands)
18.35 – 19.00	Discussion
19.00 – 20.30	Welcome reception



Friday November 7th

- 09.00 – 10:40 Mechanisms of stem and endothelial cells dysfunction in diabetic cardiovascular disease: new biomarkers or targets for therapies?
Chairmen: G. Spinetti (Italy)
 A. Avogaro (Italy)
- 09.00 – 09.20 Diabetic microangiopathy and neuropathy in bone marrow
P. Madeddu (Italy)
- 09.20 – 09.40 Circulating cells: EPCs and other "new" mononuclear cell subpopulations.
G.P. Fadini (Italy)
- 09.40 – 10.00 Non coding RNA: not only miRNAs
C. Emanuelli (UK)
- 10.00 – 10.20 Microparticles: emerging marker
G. Spinetti (Italy)
- 10.20 – 10.40 Discussion
- 10.40 – 11.00 Break
- 11.00 – 11.40 Invited Lecture
Skin fibroblasts epigenetically converted into insulin-secreting cells
G. Pennarossa (Italy)
Chairman: A Ceriello (Spain)
- 11.40 – 13.30 In cooperation with IRCCS Multimedica
Neuropathy and Angiopathy in Diabetes: renal and cardiac failure
Chairmen: P. Valensi (France)
 S. Genovese (Italy)
- 11.40 – 12.00 NGF a key factor in the dysautonomia of the ischemic heart and of diabetes
E. Vanoli (Italy)
- 12.00 – 12.20 Diabetic cardiomyopathy
A. Avogaro (Italy)
- 12.20 – 12.40 Renal failure in diabetes: the role of dysautonomia
A. Stella (Italy)
- 12.40 – 13.00 Cardiac and renal failures: the challenge!
E. Vanoli (Italy)
- 13.00 – 13.30 Discussion
- 13.30 – 14.30 Lunch



Friday November 7th

- | | |
|---------------|--|
| 14.30 – 16.00 | Oral presentations 15 min each: 6 presentations
Chairmen: J. Skra (Cech Rep.)
G. Spinetti |
| 16.00 – 16.30 | Break |
| 16.00 – 18.30 | Industry sponsored session
Oral hypoglycaemic agents and CVD
Chairmen: O. Schnell (Germany)
P. Valensi (France) |
| 16.30 – 16.50 | Sulphanilureas
E. Mannucci (Italy) |
| 16.50 – 17.10 | Pioglitazone and acarbose S
Genovese (Italy) |
| 17.10 – 17.30 | DPPIV inhibitors
N. Lalic (Serbia) |
| 17.30 – 17.50 | GLP-1-RA
A. Scheen (Belgium) |
| 17.50 – 18.10 | SGLT-2
O. Schnell (Germany) |
| 18.10 – 18.30 | Discussion |
| 18.30 – 20.00 | Oral presentations 15 min each: 6 presentations
Chairmen: J. Skra (Cech Rep.)
P. Valensi |



Saturday November 8th

- | | |
|---------------|---|
| 09.00 - 11.00 | New trend in diabetes
Chairmen: E. Standl (Germany)
D. Catrinou (Romania) |
| 09.00 - 09.20 | Residual macrovascular risk in 2014: what have we learned?
P. Valensi (France) |
| 09.20 - 09.40 | Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?
T.D. Filippatos (Greece) |
| 09.40 - 10.00 | The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions
E. Standl (Germany) |
| 10.00 - 10.20 | Sexual dysfunction and CVD in diabetes
K. Esposito (Italy) |
| 10.20 - 10.40 | The ACE trial in the context of other ongoing CV outcome trials evaluating blood glucose lowering drugs
M. Theodorakis |
| 10.40 - 11.00 | Discussion |
| 11.00 - 11.30 | Break |
| 11.30 - 13.00 | Oral presentations 15 min each: 6 presentations
Chairmen: A. Ceriello (Spain)
S. Genovese (Italy) |
| 13.30 - 14.15 | General Assembly
A. Ceriello |